{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-064762","form_type":"8-K","ticker":"HOOK","cik":"0001760542","company_name":"HOOKIPA Pharma Inc.","filed_at":"2024-05-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.937243+00:00","generated_at":"2026-06-01T09:17:14.981957+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"HOOKIPA reports HB-200 + pembro 53% ORR in CPS≥20; Phase 2/3 to start Q4 2024","bullets":["Updated data from 42 first-line HPV16+ HNSCC patients: ORR 53%, CR 18%, DCR 82% in CPS≥20 subgroup.","Median follow-up 5.6 months; grade ≥3 TRAEs in 14% of patients, no treatment-related deaths.","Neoadjuvant HB-200 + chemo showed deep responses in 81% (17/21) of HPV16+ oropharyngeal cancer patients.","HB-700 preclinical data induced KRAS mutation-specific T cell responses; Phase I planned for KRAS-mutated cancers."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-064762","json":"https://secwatch.observer/filing/0001104659-24-064762.json","markdown":"https://secwatch.observer/filing/0001104659-24-064762.md","text":"https://secwatch.observer/filing/0001104659-24-064762.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1760542/000110465924064762/0001104659-24-064762-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1760542/000110465924064762/tm2415416d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T09:17:14.981957+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}